Oncology Nursing Drug Handbook

Developer: AtmosphereApps

Category: Medical

Add App to Comparison

3.8K installs

Ratings not yet available

157 monthly active users

$<10K monthly revenue est.

IAP 100% · Ad 0%

Install Trends

Monthly +1.00

Steady

Oncology Nursing Drug Handbook Summary

Oncology Nursing Drug Handbook is a with in-app purchases Android app in Medical by AtmosphereApps. Released in May 2018 (7 years ago). It has about 3.8K+ installs Based on AppGoblin estimates, it reaches roughly 157 monthly active users and generates around $<10K monthly revenue (100% IAP / 0% ads). Store metadata: updated Apr 17, 2020.

Store info: Last updated on Google Play on Apr 17, 2020 .

SDKs, Trackers & Permissions

App not yet scanned for SDKs.

App Details

Store ID: com.atmoapps.onha

First Released: 2018-05-18

Store Last Updated: 2020-04-17

In-App Purchases: Yes

Ads: No

Website: atmosphereapps.com

App Store

Crawl Status: Success

AppGoblin First Crawled: 2021-02-06

AppGoblin Last Crawled: 2026-03-01

Ads & App-Ads.txt

App does not have ads.

AppGoblin SDK Scans

App not yet analyzed for SDKs.

The download and scan process is automated but can require manual troubleshooting. Feel free to reach out if your request does not complete in 24hrs or if you have any questions.

0★

Ratings: 0

5★

4★

3★

2★

1★

Screenshots

App Description

Written especially for nurses caring for patients with cancer.

Written especially for nurses caring for patients with cancer, the Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

New drugs include:

apalutamide (Erleada™)
calaspargase pegol-mknl (Asparlas™)
Daunorubicin and cytarabine liposome for injection (Vyxeos®)
glucarpidase (Voraxaze®)
alpelisib (Piqray®)
binimetinib (Mektovi®)
dacomitinib (Vizimpro®)
Duvelisib (Copiktra®)
encorafenib (Braftovi®)
erdafitinib (Balversa™)
lorlatinib (Lorbrena®)
anakinra (Kineret®)
baricitinib (Olumiant®)
sarilumab (Kevzara®)
aprepitant injectable emulsion (Cinvanti®)
granisetron hydrochloride extended-release injection (Sustol®)
letermovir (Prevymis™)
omadacycline (Nuzyra™)
meropenem/vaborbactam (Vabomere™)
Plazomicin (Zemdri™)
baloxavir marboxil (Xofluza™)
imipenem/cilastatin sodium/relebactam (Recarbrio™)
eravacycline (Xerava™)
delafloxacin (Baxdela™)